Rapid Micro Biosystems (RPID) Stock Price, News & Analysis

Company Overview

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting. This end-to-end approach enables continuous environmental monitoring and targeted contamination investigations, with the goal of minimizing risk in sterile and non-sterile production environments. The company also provides training, validation support and customer service to facilitate implementation and ensure regulatory compliance.

Founded and headquartered in Wilmington, Massachusetts, Rapid Micro Biosystems completed its initial public offering in mid-2021. Since inception, the company has expanded its commercial reach through a direct sales force and distribution partnerships, serving clients across North America, Europe and the Asia-Pacific region. Its instruments and consumables are integrated into quality control laboratories worldwide, supporting both small research organizations and large multinational manufacturers.

Rapid Micro Biosystems is led by a management team with extensive experience in life sciences instrumentation and pharmaceutical quality assurance. The leadership group includes professionals who have held senior roles at established diagnostics and biotech firms, combining expertise in product development, regulatory affairs and global commercialization. Under this team’s guidance, the company is focused on broadening its product portfolio and reinforcing its presence in key markets for microbial detection and environmental monitoring.

Key Stats

• Today's Range: $2.03 to $2.15
• 50-Day Range: $1.66 to $2.32
• 52-Week Range: $1.66 to $4.94
• Volume: 115,860 shs
• Average Volume: 233,420 shs
• Market Capitalization: $95.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Rapid Micro Biosystems Stock Analysis - MarketRank™

Rapid Micro Biosystems scored higher than 55% of companies evaluated by MarketBeat, and ranked 396th out of 838 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Rapid Micro Biosystems has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Rapid Micro Biosystems has a consensus price target of $6.00, representing about 191.3% upside from its current price of $2.06.

Amount of Analyst Coverage

Rapid Micro Biosystems has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rapid Micro Biosystems are expected to grow in the coming year, from ($0.94) to ($0.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rapid Micro Biosystems is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rapid Micro Biosystems is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rapid Micro Biosystems has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.83% of the float of Rapid Micro Biosystems has been sold short.

Short Interest Ratio / Days to Cover

Rapid Micro Biosystems has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rapid Micro Biosystems has recently increased by 20.27%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rapid Micro Biosystems does not currently pay a dividend.

Dividend Growth

Rapid Micro Biosystems does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rapid Micro Biosystems insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.70% of the stock of Rapid Micro Biosystems is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.60% of the stock of Rapid Micro Biosystems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 7/22/2026
• Next Earnings (Estimated): 7/31/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:RPID
• CIK: 1380106
• Web: www.rapidmicrobio.com
• Phone: 978-349-3200
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Rapid Micro Biosystems: $6.00
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: +191.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$47.12 million
• Net Margins: -145.81%
• Pretax Margin: -145.69%
• Return on Equity: -131.52%
• Return on Assets: -67.48%

Debt

• Debt-to-Equity Ratio: 0.93
• Current Ratio: 2.57
• Quick Ratio: 1.66

Sales & Book Value

• Annual Sales: $33.59 million
• Price / Sales: 2.83
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.75 per share
• Price / Book: 2.75

Miscellaneous

• Outstanding Shares: 46,170,000
• Free Float: 40,306,000
• Market Cap: $95.11 million
• Optionable: Not Optionable
• Beta: 1.46